Skip to main content

Advertisement

Table 2 Tumor response to doxorubicin in vitro treatment.

From: Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer

Patient Cell number in control samples Cell number in treated samples Cell number variation (%) Response
1 2307 1543 - 33,12 R
2 335 297 - 11,34 NR
3 2611 2472 - 5,32 NR
4 2800 2575 - 8,04 NR
5 472 216 - 54,24 R
6 445 278 - 37,53 R
7 354 304 - 14,12 NR
8 1339 1412 + 5,45 NR
9 1581 1337 - 15,43 NR
10 1405 625 - 55,52 R
11 644 656 + 1,86 NR
12 699 700 + 0,14 NR
13 5414 5086 - 6,06 NR
14 2816 2602 - 7,60 NR
15 1268 1095 - 13,64 NR
16 1851 1644 - 11,18 NR
17 11189 9691 - 13,39 NR
18 4964 3713 - 25,20 R
19 1047 1031 - 1,53 NR
20 1869 1656 - 11,40 NR
21 1629 1199 - 26,40 R
22 1675 1234 - 26,33 R
23 1879 1722 - 8,36 NR
24 2155 2103 - 2,41 NR
25 668 576 - 13,77 NR
26 4849 4262 - 12,11 NR
27 3329 3266 - 1,89 NR
28 4376 3396 - 22,39 R
29 3559 2863 - 19,56 NR
30 2716 2932 + 7,95 NR
31 4605 3569 - 22,50 R
32 5025 4242 - 15,58 NR
33 4239 4147 - 2,17 NR
34 4334 4146 - 4,34 NR
35 3691 4131 + 11,92 NR
36 5841 4659 - 20,24 NR
37 2201 2256 + 2,50 NR
38 5578 4533 - 18,73 NR
  1. Cell number was counted in control (untreated) and doxorubicin treated samples. The signal (-) stands for the percentage cell reduction and (+) for the percentage cell increase, in treated as compared to control samples. R: responsive (reduction in cell number ≥ 21.7%); NR: non-responsive (reduction < 21.7%).